Public Markets and M&AChaired by:Stephanie Leouzon, Principal and Head of Torreya Partners Europe, Torreya Partners Panellists:David Colpman, Former Head of Global Business Development at ShireKai Bruning, Senior Portfolio Manager, apo Asset Management GmbHMarco Superina, Head M&A Switzerland, Head of Healthcare M&A Europe, Credit Suisse AG Michael Shalmi, Senior Partner, Novo A/SNicholas Franco, Executive VP & Chief BD Officer, Actelion Pharmaceuticals LtdSascha Alilovic, VP Corporate Finance & Corporate Development, MorphoSys AG Tim Mitchell, CEO, Sareum Ltd.

Registration & Coffee

Welcome Speech by Beth Jacobs, Managing Partner, Excellentia Global Partners

“Global M&A: a Novartis Perspective” by Anthony Rosenberg, Head of M&A and Licensing, Novartis Pharma AG

Autoimmune & InflammatoryChaired by: Florent Gros, Managing Director in Basel, Novartis Venture FundPanellists:Adrian Mills, CBO, NovImmune SAErik van den Berg, CEO, AM-PharmaJan-Anders Karlsson, CEO, Verona Pharma plcPierre Vandepapeliere, CMO, Neovacs

VaccinesCo-Chaired by:Chris Britten, Head, Business Development, Sanofi Pasteur MSD Florian Schoedel, Owner, Philimmune, LLCPanellists:Chip Clark, CEO, Genocea Biosciences, Inc.David Anderson, C-Founder & SVO, VBI VaccinesHartmut J. Ehrlich, CEO, ABIVAXRainer Henning, CEO, BiomaySara Nunez-Garcia, Associate in Life Sciences, Sofinnova PartnersThomas Johnston, CEO, Mucosis B.V.

Coffee Break

Keynote Speech by Reinhard Ambros, Global Head, Novartis Venture Fund

InvestmentChaired by:Genghis Lloyd-Harris, Partner, Abingworth LLPPanellists:Barbara Dalton, VP Venture Capital, Pfizer Inc.Björn Odlander, Founding Partner, HeathCapCarole Nuechterlein, Head of Roche Venture Fund BaselChristopher Earl, Senior Advisor, Merck Research Laboratories VenturesDeborah Harland, General Partner, SR OneJanis Naeve, Executive Director (Corporate Development), Amgen Ventures Markus Hosang, General Partner, BioMedPartners AG

Oncology I – Building the Cancer Focused BiotechCo-Chaired by:Esteban Pombo-Villar, COO, Oxford BioTherapeuticsKatya Smirnyagina, Partner, Capricorn Venture PartnersPanellists:Bernhard Sixt, CEO, ImmunIDCarlos Buesa, CEO, ORYZONJohn Haurum, CEO, F-StarGuillaume Vignon, Director of Global BD and Licensing, EMD Serono Philip Serlin, CEO, BioLineRxPeter Sandor, VP, Global Marketing, TA Head Oncology, AmgenRobert H. Pierce, Chief Medical Officer, OncoSecStephen Sands, Commercial Lead Oncology/Immunology, Hoffmann-La Roche AG Vladimir Cmiljanovic, CEO, Piqur Therapeutics AG

Orphan & Rare DiseasesChaired by: David Phillips, Partner, SR OnePanellists:Anders Hinsby, CEO, ORPHAZYMESten Verland, Partner, Sunstone Capital A/S, Life Science VenturesStephen Helliwell, Senior Investigator, Novartis Institutes of Biomedical Research, NovartisPatrick Krol, Managing Partner, Aescap Venture

Personalised Medicine & DiagnosticsCo-Chaired by:Markus Ewert, EVP Business Development, GE HealthcareRainer Strohmenger, General Partner, Wellington PartnersPanellists:Alain Huriez, Venture Partner, Advent Life SciencesChristiane Smerling, Head of Nuclear Medicine & Imaging, 3B Pharmaceuticals GmbH Guy Greiveldinger, Director BD&L and M&A, Novartis Pharma AGMiro Venturi, Head Oncology Biomarkers, Roche Pharma Research & Early Development Rainer Metzger, VP Global Business Development Pharma, QIAGEN GmbH

CV & Metabolic DiseasesChaired by:Christoph Pittius, VP, Head of Transactions, BD, Global Product and Portfolio Strategy, AstraZenecaPanellists:Bernard Coulie, CEO, ActoGeniXJohannes Zanzinger, Global Head, CardioMetabolic BD and Licensing, Boehringer Ingelheim Ignacio Faus, CEO, Genmedica TherapeuticsMichael Kranda, CEO, BEAT Biotherapeutics Corp.Roman Schenk, CEO, RECARDIO GmbH

14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment, 30th September - 1st October, Congress Center Basel

08.00

08.45

09.00 Genocea BioSciences, Inc.

10.00

09.00

09.00

09.45

10.30

10.45

11.00

12.00

10.45

11.30

12.15

09.00 APEPTICO

09.10 Oncos Therapeutics Ltd. 09.10 BioLingus

09.20 PDC*line Pharma 09.20 Genkyotex SA

09.30 GamaMabs Pharma 09.30 Cellphire, Inc.

09.40 NBE-Therapeutics 09.40 Eyevensys

09.50 InnoMedica 09.50 NovaHep AB

10.00 Rexahn Pharmaceuticals 10.00

RECARDIO GmbH

10.10 Humabs BioMed SA 10.10 Genmedica Therapeutics

10.20 BioVersys AG 10.20

ProFactor Pharma Ltd.

10.45 Aptose Biosciences Asceneuron SA

11.00 Actinium Pharmaceuticals BioCrea

11.15

Sareum Ltd.

Canbex Therapeutics Limited

11.30 Nanobiotix SA Heptares Therapeutics

11.45

BioLineRx Ltd.

Targeted Medical Pharma, Inc.

12.00 RedHill Biopharma Pharmaco-Kinesis Corporation

12.15 Immune Pharmaceuticals Inc. to-BBB

12.30 Metys Pharmaceuticals Serodus ASA

12.45 MaxCyte, Inc. Orphazyme ApS

10.45

11.00

11.15

11.30

11.45

12.00

12.15

12.30

12.45

Presentation Track C - Room DarwinModerated by: Lynn Trowbridge

Presentation Track D - Room LimaModerated by: Tomas Kahn

Presentation Track A - Room DarwinModerated by: Martina Kaufmann

Presentation Track B - Room LimaModerated by: Robin Davison

10.15 TBC

ROOMBOSTON

ROOMBOSTON

ROOMDELHI

ROOMDELHI

ROOMDELHI

ROOMDELHI

ROOMDELHI

ROOMBOSTON

Tuesday, 30th September

Sachs WIFIID: 2093377583PSW: 8748

Interview by Simeon Bennett, Bloomberg News:Iris Welten, CEO, Basel Area

16.10 -16.25

Networking Lunch

Oncology II - Next Gen ImmunotherapeuticsCo-Chaired by:Esteban Pombo-Villar, COO, Oxford BioTherapeuticsTim Herpin, Vice President, Head of Transactions (UK), BD, AstraZeneca Panellists:Daniel Teper, CEO, Immune Pharmaceuticals Inc.Dragan Cicic, COO and CMO, Actinium PharmaceuticalsPhilippe Mauberna, CEO, NanobiotixRichard Goodfellow, CEO, ScancellKeith Blundy, CEO, Cancer Research Technology

Infectious DiseasesChaired by:Laurenz Kellenberger, CSO, BasileaPanellists:Ian Nicholson, CEO, F2G Ltd.John A.T. Young, Global Head Discovery, Infectious Diseases, Roche Pharma Research & Early Development, Roche Innovation Center BaselNicholas Benedict, CEO & Co-Founder, Allecra Therapeutics

Oncology III – Cell, Gene & Other New TherapiesChaired by:Francois Thomas, Managing Director, Thomas Conseil SPRL Panellists:Andre Choulika, Chairman and CEO, Cellectis Doug Doerfler, President & CEO, MaxCyte, Inc.Eric Falcand, Head of Alliance Management and US licenses, SERVIER

IsraelChaired by: Laurent Choppe, Managing Partner, Cukierman & Co. Life SciencesPanellists:Dan J. Gelvan, Managing Director, Life Sciences, Aurum Ventures MKI Ltd.Guy Goldberg, CBO, RedHill Biopharma LtdOra Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, Israel Orna Palgi, EVP of Research and Development, Otic Pharma Ltd.

Interview by Simeon Bennett, Bloomberg News:Dr Sophie Kornowski-Bonnet, Head of Roche Partnering

NeuroscienceChaired by: Chris Maggos, ConsultantPanellists:Dirk Beher, CEO, ASCENEURON SAJesse Schulman, CEO, Canbex Therapeutics LtdJonathan Garen, Assistant VP Business Development, Actavis plc Laxminarayan Bhat, Founder and CEO, Reviva Pharmaceuticals Inc. Malcolm Weir, Co-Founder and CEO, Heptares TherapeuticsTom Kronbach, CEO, BioCreaWilliam Shell, CEO, Targeted Medical Pharma, Inc.

Platform Technologies & Novel TherapeuticsCo-Chaired by:Christina Takke, Partner, Forbion Capital PartnersRobin Davison, Director, Healthcare, Edison Investment ResearchPanellists:Daniel Elger, Chief Financial & Corporate Development Officer, Genkyotex SA Doug Doerfler, President & CEO, MaxCyte, Inc.Elena Startseva, Head of Business Development, OCTDavid Urech, Co-CEO & CSO, Numab AGPhilippe Calais, CEO, Isarna Therapeutics GmbHTim Knotnerus, Director Business Development, AM-PharmaVikas Sharma, Director, Business Development, Rexahn Pharmaceuticals, Inc. Vincent Charlon, CEO, Anergis SA

Human Biome & NutritionIntroductory Speech by:Prof Gary Frost, Professor of Nutrition and Dietetics, Imperial CollegeChaired by:Rao Movva, Novartis Distinguished Scientist, Executive Director, DMP/NIBR/Novartis Pharma AG Panellists:Avi Spier, Director, Strategic Alliances, Novartis Institutes for BioMedical Research, Inc.Lothar Steidler, Vice President Technology, ActoGeniXPeter DiLaura, President and CEO, Second GenomeRodolphe Clerval, Chief Business Officer & Co-Founder, ENTEROMEScott Parkinson, Head of Gastrointestinal Health & Microbiome, Nestle Institute of Health Sciences SA

End of the Forum

Networking Reception hosted by Kanton Basel-Stadt at the Grand Hotel Les Trois Rois

End of Reception

13.00

14.00

14.45 - 15.30

14.00

14.45

15.40 -16.10

15.30

16.30

16.30

18.00

19.00

21.00

14.00 PCI Biotech

AM-Pharma B.V.14.15 ANERGIS SA

Amarantus BioScience

14.30 Isarna Therapeutics Actogenix NV

14.45 ImmunID BEATBio Therapeutics

15.00 Numab AG Verona Pharma plc

15.15 Scil Proteins Cortendo AB

15.30 Oryzon Genomics CEVEC

15.45 Karus Therapeutics Ltd. BIOMAY AG

16.05 PIQUR Therapeutics AG Mucosis B.V.

16.20 F-star Biotechnology Ltd. VBI Vaccines

16.35 OncoSec Medical, Inc. Scancell

16.50 Biophytis Lixte Biotechnology Holdings, Inc.

17.05 Russian Pharmaceutical Technologies MC2 Biotek

17.15 Inthera Bioscience AG Clanotech AB

17.25 Synthena AG Takis s.r.l.

17.35 Reviva Pharmaceuticals, Inc. Acousia Therapeutics GmbH

17.45 DORPHAN Minoryx Therapeutics

14.00

14.15

14.30

14.45

15.00

15.15

15.30

15.45

16.05

16.20

16.35

16.50

17.05

17.15

17.25

17.35

17.45

Presentation Track F - Room LimaModerated by: Hans Herklots

Presentation Track E - Room DarwinModerated by: Joergen Thorball

Presentation Track H - Room LimaModerated by: Lorenza Castellon

Presentation Track G - Room DarwinModerated by: Jason Rushton

Presentation Track J - Room BostonModerated by: Stephanie Leouzon

17.30 VTU Technology GmbH

17.45 F2G Limited17.55 TBC 17.55 TBC

ROOMDELHI

ROOMDELHI

ROOMDELHI

ROOMBOSTON

ROOMBOSTON

ROOMBOSTON

ROOMDELHI

Registration & Coffee

14th Annual Biotech in Europe Investor Forum for Global Partnering and Investment, 30th September - 1st October, Congress Center Basel

08.00

09.00

Partnering I – External Innovation Opportunities: Strategies & TacticsCo-Chaired by:Fintan Walton, CEO and Founder, PharmaVenturesWilder Fulford, Principal, Torreya PartnersPanellists:Andrew Mackie, Global External R&D, Eli Lilly and CompanyFrank Grams, VP Head R&D Alliance Management & Contracting, SanofiJason Coloma, Global Head Venture & Innovation at Roche Partnering, F. Hoffmann La Roche AGJohan Verbeeck, Senior Director Alliance Management, J&J Innovation Center, Janssen Pharmaceutical Companies of J&J John Gustofson, Sr. Director, Venture and Early Stage Collaborations, AbbViePaola Casarosa, Corp. Vice President of Therapeutic Alliances and Strategic Partnerships, Boehringer IngelheimTomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk

Partnering II – Deal Making: The Evolving Landscape of Deal TermsCo-Chaired by:Fintan Walton, CEO and Founder, PharmaVenturesWilder Fulford, Principal, Torreya PartnersPanellists:Carlos de Sousa, Chief Business Officer, to-BBBCorinne Savill, Head BD&L, Novartis Pharma AGLubor Gaal, Head of Europe, Search & Evaluation, Business Development, Bristol-Myers SquibbLuca Bolliger, VP and Group Licensing Director, RECORDATI S.A. Philippe Lopes-Fernandes, Global Business Development, Merck Serono Stewart Kay, Director, Transactions, GlaxoSmithKline

Scientific CollaborationIntroductory Speech by:Ora Dar, Head of Life Sciences Sector, Office of the Chief Scientist, Ministry of Economy, IsraelChaired by:Beth Jacobs, Managing Partner, Excellentia Global PartnersPanellists:Chris Maggos, ConsultantEdwin Constable, Head of Research, Professor of Chemistry at the University of Basel and Projectleader and Member of the Management Board within the SNI, University of BaselFlorian Schoedel, Owner, Philimmune, LLCMaina Bhaman, Director, Healthcare Ventures, Imperial InnovationsPrem Das, Chief Research Business Development Officer and heads DFCI’s Office of Research and Technology Ventures (ORTV), Dana- Farber Cancer Institute (DFCI)

When Price Gives Way to Value: Implications for Deal MakingChaired by:Ed Saltzman, President, Defined HealthPanellists:Anita Riyat, Director, Corporate Strategy, AbbVie Inc.Chandra Leo, Investment Advisor, Private Equity Team, HBM Partners AGDavid Alderson, EU Practice Lead, Global Market Access Consulting, EvideraWilder Fulford, Principal, Torreya Partners

Early Stage InvestmentCo-Chaired by:Hakan Goker, Director, MS VenturesDavid Sabow, Head of Life Sciences, Silicon Valley Bank Panellists:Bernd Goergen, Investment Director, High-Tech Gruenderfonds Management GmbHFrank Kalkbrenner, Head Boehringer Ingelheim Venture Fund, Boehringer Ingelheim GmbHSøren Møller, Managing Investment Director, Novo A/SUlf Grawunder, CEO, NBE Therapeutics GmbH

Drug Development and ManufacturingChaired by:Lorenza Castellon, Business Development Consultant, Suda Ltd. Panellists:Ales Strancar, CEO, BIA SeperationsGuillaume Plane, Global Product Manager - BioDevelopment Services ProcessSolutions, Merck MilliporeMike Bastian, BD Manager, Birken AGMohamed Homman, CEO, Vironova AB

10.00

09.00 LINDIS Biotech GmbH

09.10 Otic Pharma

09.20 ENTEROME

09.30 OssDsign AB

09.40 AFreeze GmbH

09.50 Blueprint Genetics

10.00 PhosImmune, Inc. 10.00 3B Pharmaceuticals GmbH

10.15 Abzena10.10 ABIVAX

10.30B Cell Design

10.20 CAP-CMV GmbH

10.45Vironova

10.30 G7 Therapeutics

11.15Dipexium Pharmaceuticals, Inc. 11.15 Re-Pharm

11.30 Actavis11.25 ugichem GmbH

11.45CoDa Therapeutics Inc.

11.35 Arisgen SA

12.00 OCT

11.45 Palobiofarma, SL

12.15

Dana-Farber Cancer Institute

11.55 Critical Pharmaceuticals

12.30NovImmune SA

12.05 Obexia AG

Coffee Break11.00

11.15

12.15

11.15

12.00

10.40 Mymetics

10.50 TBC

12.15 Lykera Biomed

12.25 CARLINA Technologies

12.35 eNovalys

Presentation Track B - Room DarwinModerated by: Hans Herklots

Presentation Track A - Room LimaModerated by: Lorenza Castellon

12.45

13.00BIA Seperations

NEOVACS

Presentation Track C - Room DarwinModerated by: TBC

Presentation Track D - Room LimaModerated by: Joergen Thorball

12.45 TBC

12.55 TBC

13.05 TBC

ROOMBOSTON

ROOMBOSTON

ROOMBOSTON

ROOMBOSTON

ROOMDELHI

ROOMDELHI

Wednesday, 1st OctoberSachs WIFIID: 2093377583PSW: 8748

Networking Lunch

Conference Workshop: “Conundrums and Conflicts in Licensing & M&A Deals” - An interactive workshop considering ethical dilemmas and challenges in biopharmaceutical deal making Workshop facilitators: Nigel Borshell, VP, and Fintan Walton, Chief Executive, PharmaVentures Ltd

NetworkingEnd of the Forum

13.15

14.15

16.0017.00

ROOMBOSTON